News OPKO Health, Inc.

Equities

OPK

US68375N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.28 ^USD	+1.59%		-1.54%	-15.23%

May. 07	Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	MT
May. 07	Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	May. 07	MT
OPKO Health: Q1 Earnings Snapshot	May. 07	AQ
Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results	May. 07	AQ
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024	May. 06	AQ
OPKO Health : Immediate Report	May. 04	PU
OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024	May. 03	AQ
InvestorBrandMedia: Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. (NYSEAMERICAN: ATNM) Amidst Groundbreaking Cancer Therapy Innovations	Apr. 01	AQ
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	AQ
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
OPKO Health : Immediate Report	Mar. 15	PU
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
OPKO Health - AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 06	AQ
AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV	Mar. 05	AQ
OPKO Health : Immediate Report	Mar. 02	PU
OPKO Health : Report of Periodic or Interim Report	Mar. 02	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News OPKO Health, Inc.

Equities

OPK

US68375N1037

Summary

Filters